Published in Transplantation on March 01, 2016
Multiple links between transcription and splicing. RNA (2004) 4.90
DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell (2009) 3.66
Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol (2009) 3.47
The transcriptional cycle of HIV-1 in real-time and live cells. J Cell Biol (2007) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 2.49
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Acute liver failure in Spain: analysis of 267 cases. Liver Transpl (2007) 1.71
The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. Crit Care Med (2011) 1.70
The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem Sci (2010) 1.67
Hemodynamic profile and tissular oxygenation in orthotopic liver transplantation: Influence of hepatic artery or portal vein revascularization of the graft. Liver Transpl (2006) 1.65
Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol (2002) 1.64
Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.61
Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl (2009) 1.55
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53
Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis (2008) 1.51
Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation (2007) 1.51
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation (2006) 1.49
Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl (2008) 1.48
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS (2006) 1.44
[Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases]. Cir Esp (2008) 1.44
[Impact of a non-compulsory antibiotic control program (PACTA): cost reductions and decreases in some nosocomial infections]. Enferm Infecc Microbiol Clin (2005) 1.43
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
[Gastrointestinal and pancreatic neuroendocrine tumors]. Med Clin (Barc) (2006) 1.42
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl (2011) 1.40
Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg (2004) 1.35
Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol (2002) 1.33
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol (2005) 1.23
Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol (2006) 1.23
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology (2005) 1.22
Hilar dissection versus the "glissonean" approach and stapling of the pedicle for major hepatectomies: a prospective, randomized trial. Ann Surg (2003) 1.20
Blood and urine samples as useful sources for the direct detection of tuberculosis by polymerase chain reaction. Diagn Microbiol Infect Dis (2006) 1.16
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transpl (2009) 1.13
The spectrum of cardiovascular infections due to Salmonella enterica: a review of clinical features and factors determining outcome. Medicine (Baltimore) (2004) 1.13
Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int (2003) 1.05
Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) (2014) 1.04
Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS (2010) 1.04
Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation (2002) 1.04
Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation (2007) 1.03
Predictive factors for early mortality following liver transplantation. Clin Transplant (2003) 1.01
Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clin Chem (2012) 0.98
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl (2006) 0.98
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol (2006) 0.97
N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact (2009) 0.96
Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl (2010) 0.94
Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin Transplant (2011) 0.93
Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection? Liver Transpl (2010) 0.92
Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One (2012) 0.92
Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J Hepatol (2010) 0.91
Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl (2011) 0.91
Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl (2008) 0.91
[GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin (2005) 0.90
Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol (2002) 0.90
Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis (2005) 0.90
Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver Int (2008) 0.90
Unraveling the S-nitrosoproteome: tools and strategies. Proteomics (2009) 0.90
Successful reuse of liver grafts after death of the first recipient. Clin Transplant (2006) 0.90
Interferon gamma quantification in cerebrospinal fluid compared with PCR for the diagnosis of tuberculous meningitis. J Neurol (2006) 0.89
Bilateral adrenal metastases from hepatocellular carcinoma after liver transplantation. Hepatogastroenterology (2002) 0.89
Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. J Hepatol (2011) 0.88
Endoscopic closure of duodenal perforation with an over-the-scope clip during endoscopic ultrasound-guided cholangiopancreatography. Rev Esp Enferm Dig (2012) 0.88
Control of alternative pre-mRNA splicing by RNA Pol II elongation: faster is not always better. IUBMB Life (2003) 0.88
Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw (2010) 0.88
GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin (2011) 0.88
Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg (2004) 0.87
Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One (2013) 0.87
Incisional surgical site infection in kidney transplantation. Urology (2008) 0.86
Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre. Hepatol Int (2010) 0.86
Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol (2012) 0.85
Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol (2006) 0.85
HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals. Hum Immunol (2003) 0.85
Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. Liver Transpl (2013) 0.84
Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg (2010) 0.84
[Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) (2009) 0.84
Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int (2005) 0.83
Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl (2009) 0.83
Our experience in liver transplantation in patients over 65 yr of age. Clin Transplant (2008) 0.83
Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol (2013) 0.83
Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int (2014) 0.83
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients. Transplantation (2013) 0.82
Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. Transplantation (2010) 0.82
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl (2009) 0.82
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. AIDS (2012) 0.82
PGE1-induced NO reduces apoptosis by D-galactosamine through attenuation of NF-kappaB and NOS-2 expression in rat hepatocytes. Hepatology (2004) 0.82
Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients. Transplantation (2012) 0.81
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc) (2009) 0.81
Genetic and epigenetic markers in the evaluation of pancreatic masses. J Clin Pathol (2012) 0.81
Donor-recipient matching: myths and realities. J Hepatol (2012) 0.81
Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models. Hum Gene Ther (2006) 0.81
Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World J Hepatol (2010) 0.81